Day One Biopharmaceuticals, Inc.

Privately held: no public share price

Assets

(1 total)
1Total Assets
1Approved
0Phase 3 / Filed
0Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Approved
Kinase InhibitorSmall molecule
Glioma

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (2)
May 2027 (1)
TovorafenibPhase 2Low-grade Glioma, Advanced Solid Tumor
Est. primary completion 2027-05-31 · NCT04775485 · CT.gov ↗
What to watch
June 2027 (1)
TovorafenibPhase 3Low-grade Glioma, Rapidly Accelerated Fibrosarcoma (RAF) Altered Glioma, Pediatric Low-grade Glioma
Est. primary completion 2027-06 · NCT05566795 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

No financial reports recorded.